This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Nektar Therapeutics. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Jicai Huang: Innovator in Protein Conjugation
Introduction
Jicai Huang is a notable inventor based in San Mateo, CA (US). He has made significant contributions to the field of biotechnology, particularly in the area of protein conjugation. His work focuses on enhancing the efficacy of therapeutic proteins, which has important implications for medical treatments.
Latest Patents
Jicai Huang holds a patent for a "Method of refolding an interleukin-2 (IL-2) protein." This patent involves conjugates of an interleukin-2 moiety and one or more nonpeptidic, water-soluble polymers. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. The patent also covers compositions comprising these conjugates, methods of making them, and methods for administering the compositions to individuals. Additionally, it includes nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties. Jicai Huang has 1 patent to his name.
Career Highlights
Jicai Huang is currently employed at Nektar Therapeutics, a company known for its innovative approaches in drug development. His work at Nektar Therapeutics has allowed him to collaborate with other talented professionals in the field, further advancing the research and development of therapeutic solutions.
Collaborations
One of his notable coworkers is Yujun Wang, with whom he has likely collaborated on various projects related to protein conjugation and therapeutic applications.
Conclusion
Jicai Huang's contributions to the field of biotechnology, particularly through his patent on interleukin-2 protein conjugation, highlight his role as an innovator in the industry. His work at Nektar Therapeutics continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
